Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV

Yonkers, NY, February 25, 1999 - Advanced Viral Research Corp. (OTC BB:ADVR) announced today that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose markedly decreased the number of cellular CCR5 receptors. The CCR5 receptor is one of the three most important cell receptors needed by the AIDS virus, HIV, to attach to its target cells and initiate infection.

Interference with the function of the CCR5 cellular chemokine receptor is known to increase the resistance of T-lymphocytes and macrophages to HIV infection. A mutation in the CCR5 gene, especially prevalent in individuals of northern European descent, appears to render these individuals resistant to infection by HIV.

Commenting on this research, Dr. Shalom Z. Hirschman, President and CEO of Advanced Viral Research Corp., stated "The exciting discovery by our scientists that the immunomodulator, Reticulose, interferes with the production of the CCR5 receptor offers a novel approach to the development of therapeutic agents for HIV infection. This new finding may account, in part, for the beneficial effects of Reticulose in the treatment of HIV infected individuals observed in preliminary clinical trials. Furthermore, this new pathway of inhibiting HIV infection suggests that combination therapy with Reticulose may enhance the therapeutic effectiveness of the AIDS cocktails currently in use."

Reticulose is a peptide nucleic acid preparation produced by Advanced Viral Research Corp. which, based on previous history, has been show to be effective against a number of viral diseases. For further information, contact Mark Amster at 954-458-7636.


Contact: William Bregman
Advanced Viral Research Corp.

Page: 1

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. New Model Makes It Possible To Predict Emergence Of Antiviral Drug Resistance
4. Advanced sensors, computing systems tracking sea animals worldwide
5. Statement by the Ethics Advisory Board of Advanced Cell Technology, Inc.
6. UC Irvine Advanced Power and Energy Program awarded $3 million grant by California Energy Commission
7. X-ray crystallography at Advanced Photon Source
8. University of Washington partners with Advanced Tissue Sciences and others in $10 million grant to grow human heart tissue
9. Advanced cell technology reports reversal
10. Advanced light source reveals secrets of ribosome structure
11. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center

Post Your Comments:

(Date:6/16/2019)... ... June 14, 2019 , ... Emtec, Inc.®, a ... a joint presentation with Versiti’s CIO at the Healthcare Industry User Group ... Creek Resort. , Versiti Vice President and Chief Information Officer, Lynne Briggs, will ...
(Date:6/11/2019)... AUCKLAND, New Zealand (PRWEB) , ... June 12, ... ... a wide range of antibody discovery services, Abveris plans to leverage the Geneious ... , Dr. Colby Souders, Chief Technology Officer at Abveris, says: “The Geneious ...
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... ... role as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its ... a preeminent anatomic pathology platform that provides services to more than one dozen ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... May 30, 2019 , ... World Compliance Seminars today announced ... 2019 in Boston, MA. This peer recommended interactive workshop is always selected by ... will kick off with a compendial treatment of Data Integrity fundamentals. After laying ...
(Date:5/15/2019)... ... ... Milton Hershey School® has named William Charles Ballough Harding ’78 the 2019 ... he is changing lives by creating solutions to global healthcare challenges through the development ... our founders – Milton and Catherine Hershey – who always hoped for Milton Hershey ...
(Date:5/7/2019)... ... 06, 2019 , ... "The new Liquid Nitrogen Best Practices ... asked to store cellular products being used in adoptive therapy research and ... leaders, who have shared their expertise in building and managing facilities to support ...
(Date:5/2/2019)... TORONTO (PRWEB) , ... May 02, 2019 , ... Stay ... pharma, biotech, medical device and food industries. Access to all webinars is free, so ... stay relevant in your field! , Visit http://www.xtalks.com to see our upcoming ...
Breaking Biology Technology:
Cached News: